But those who are in a much more informed position are not buying, including the new directors of the company.
As I see it, most of the decisions which might change things are outside SPL control like:
- AZ moving to Phase 2 of the clinical trial,
- TGA approving Viraleze,
- Other partners signing agreements,
- FDA changing their minds on Vivagel,
- Mundipharma deciding to distribute as it agreed to,
- Anyone advertising the Viraleze web site,
- Anyone showing a commercial interest in the in house DEP trials,
- Medical authorities in Australia telling women that Fleurstat is a treatment and preventative for BV (after five years in the pharmacies).
So everyone waits in complete ignorance of what is going on. But then, we are used to that. If there was any good news then JF would have been telling us, like the remarkable DEP results (still not published), like the distribution deals (still not distributing).
What a sick joke!
SPL Price at posting:
45.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)